Effects of pilocarpine- and kainate-induced seizures on thyrotropin-releasing hormone biosynthesis and receptors in the rat brain.
The expression of mRNA coding for prepro-thyrotropin releasing hormone (preproTRH) was estimated in the rat brain in two animal models of limbic seizures, evoked by systemic administration of pilocarpine (400 mg/kg ip) or kainate (12 mg/kg ip). As shown by an in situ hybridization study, after 24h both pilocarpine- and kainate-induced seizures profoundly increased the preproTRH mRNA level in the dentate gyrus. After 72h, the preproTRH mRNA level was back to control values. Kainate-treated rats showed an elevated level of TRH in the hippocampus, septum, frontal and occipital cortex after 24 and 72h, whereas in the striatum and amygdala the TRH level was raised after 72h only. In the hypothalamus, TRH levels was lowered after 3 and 24h, and returned to the control after 72h. Pilocarpine-induced seizures also elevated the TRH level after 72h in the majority of the above structures, except for the hypothalamus and amygdala where no changes were found at any time point. A radioreceptor assay showed that kainate decreased the Bmax value of TRH receptors in the striatum and hippocampus after 3 and 24h, respectively, and had no effect on the Kd values. In contrast, pilocarpine-induced seizures lowered the Bmax of TRH receptors in the striatum, hippocampus and piriform cortex after 72h only, and decreased Kd values in the striatum, amygdala and frontal cortex. These data showed that pilocarpine- and kainate-induced seizures enhanced likewise preproTRH mRNA in the dentate gyrus; on the other hand, they differed with respect to time- and structure-related changes in TRH tissue levels and TRH receptors. These differences may have functional significance in TRH-dependent control mechanism of the seizure activity in these two models of limbic epilepsy.
Jaworska-Feil
L
L
Department of Endocrinology, Institute of Pharmacology, Polish Academy of Sciences, Kraków.
Turchan
J
J
Przewłocka
B
B
Budziszewska
B
B
Leśkiewicz
M
M
Lasoń
W
W
D000679:Amygdala / Q000378:metabolism; D000818:Animals; D001483:Base Sequence; D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D003342:Corpus Striatum / Q000378:metabolism; D018891:Dentate Gyrus / Q000378:metabolism; D005625:Frontal Lobe / Q000378:metabolism; D005786:Gene Expression Regulation / Q000187:drug effects / Q000502:physiology*; D007031:Hypothalamus / Q000378:metabolism; D007608:Kainic Acid / Q000494:pharmacology*; D008297:Male; D008969:Molecular Sequence Data; D009778:Occipital Lobe / Q000378:metabolism; D009928:Organ Specificity; D010862:Pilocarpine / Q000494:pharmacology*; D011498:Protein Precursors / Q000235:genetics; D012333:RNA, Messenger / Q000235:genetics; D011869:Radioligand Assay; D051381:Rats; D017208:Rats, Wistar; D018025:Receptors, Thyrotropin-Releasing Hormone / Q000096:biosynthesis / Q000235:genetics*; D012640:Seizures / Q000139:chemically induced / Q000378:metabolism*; D013973:Thyrotropin-Releasing Hormone / Q000096:biosynthesis / Q000235:genetics*; D013997:Time Factors; D014158:Transcription, Genetic / Q000187:drug effects / Q000502:physiology*
D011498:Protein Precursors; D012333:RNA, Messenger; D018025:Receptors, Thyrotropin-Releasing Hormone; D010862:Pilocarpine; C063596:prepro-thyrotropin-releasing hormone; D013973:Thyrotropin-Releasing Hormone; D007608:Kainic Acid